Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-10-28Actual
Enrollment · participants187Actual
Source updated2024-04-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.